Compare TBPH & SMBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | SMBK |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 777.3M |
| IPO Year | 2013 | 2000 |
| Metric | TBPH | SMBK |
|---|---|---|
| Price | $16.91 | $46.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $18.40 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 905.3K | 105.6K |
| Earning Date | 05-04-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 0.77% |
| EPS Growth | ★ 279.13 | 39.25 |
| EPS | N/A | ★ 0.81 |
| Revenue | ★ $15,386,000.00 | N/A |
| Revenue This Year | $8.46 | $17.59 |
| Revenue Next Year | N/A | $10.30 |
| P/E Ratio | ★ N/A | $57.80 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.82 | $32.64 |
| 52 Week High | $21.03 | $49.07 |
| Indicator | TBPH | SMBK |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 59.98 |
| Support Level | $16.12 | $40.28 |
| Resistance Level | $17.21 | $49.07 |
| Average True Range (ATR) | 0.22 | 1.17 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 1.75 | 43.62 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.